Synapse - Carol Portlock

Search Within

Carol Portlock

Results (206)

Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent

Journal Article

Teckie, S.; Qi, S.; Lovie, S.; Navarrett, S.; Hsu, M.; Noy, A.; Portlock, C.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2015)

Fulltext@MSK | Save

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study

Journal Article

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Lancet Oncology (2015)

Fulltext@MSK | Save

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

Journal Article

Vijai, J.; Wang, Z. M.; Berndt, S. I.; Skibola, C. F.; Slager, S. L.; De Sanjose, S.; Melbye, M.; Glimelius, B.; Bracci, P. M.; Conde, L.; more...
Nature Communications (2015)

Fulltext@MSK | Save

Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition

Journal Article

Mehta, N.; Schöder, H.; Chiu, A.; Schoolmeester, J. K.; Portlock, C.
BMJ Case Reports (2014)

Fulltext@MSK | Save

Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile

Meeting Abstract

Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
Blood (2014)

Fulltext@MSK | Save

Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
Blood (2014)

Fulltext@MSK | Save

Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma

Meeting Abstract

Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
Blood (2014)

Fulltext@MSK | Save

Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects

Meeting Abstract

Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay

Meeting Abstract

Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
Blood (2014)

Fulltext@MSK | Save

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins

Journal Article

Ng, P. P.; Kuo, C. C.; Wang, S.; Einav, S.; Arcaini, L.; Paulli, M.; Portlock, C. S.; Marcotrigiano, J.; Tarr, A.; Ball, J.; more...
Blood (2014)

Fulltext@MSK | Save